查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1986283

美国人工智慧糖尿病视网膜病变筛检市场：市场规模、份额和趋势分析（按组件、筛检方法、部署方法和最终用途划分），细分市场预测（2026-2033 年）

U.S. AI-driven Diabetic Retinopathy Screening Market Size, Share & Trends Analysis Report By Component, By Screening, By Deployment Mode, By End Use, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国人工智慧驱动的糖尿病视网膜病变筛检市场概述

据估计，到 2025 年，美国人工智慧驱动的糖尿病视网膜病变筛检市值为 1.9001 亿美元，预计到 2033 年将达到 8.8174 亿美元。

预计从 2026 年到 2033 年，市场将以 21.18% 的复合年增长率成长。糖尿病盛行率上升、有利的保险报销方案、眼科医生短缺以及医疗保健服务取得方面的不平等是市场成长的关键驱动因素。

在美国，糖尿病已成为日益严峻的公共卫生挑战，导致越来越多的人面临糖尿病视网膜病变的风险。例如，根据美国疾病管制与预防中心（CDC）2024年5月发布的数据，约有3,840万人患有糖尿病，占美国总人口的11.6%。此外，美国眼科学会（AAO）的报告显示，儘管有明确的临床指南，但仍有近60%的糖尿病患者未接受建议的年度散瞳眼底检查。这种建议治疗与实际依从性之间的差距显着增加了疾病未确诊进展并导致可预防性视力丧失的风险。

虽然糖尿病患者通常在基层医疗或内分泌科接受治疗，但这些科室往往无法提供视网膜筛检。随着糖尿病盛行率的上升，年度眼科检查的需求已超过现有专家的服务能力。这导致筛检负担沉重，而传统医疗系统难以有效应对。人工智慧 (AI) 驱动的糖尿病视网膜病变筛检系统提供了一种扩充性的临床级解决方案，无需专科医生即时介入。 AI 透过自主快速诊断弥补了检测方面的不足。此外，将其整合到基层医疗中，使非专科医生也能使用该系统，从而实现早期疗育，预防视力丧失和併发症。例如，2023 年 7 月，西奈山医院成立了纽约首个眼科人工智慧与人类健康中心，推动了 AI 在眼科领域的应用，以实现对黄斑部病变、糖尿病视网膜病变、青光眼、高血压性视网膜病变和视网膜肿瘤的及时诊断。该中心与温德赖希人工智慧与人类健康学院合作，利用检验的人工智慧模型，推广远端视网膜诊断、远端眼科咨询和眼科中风治疗。

此外，2021年，美国联邦医疗保险（Medicare）引入了新的人工智慧糖尿病视网膜病变筛检报销代码，显着推进了人工智慧辅助眼科疾病诊断的发展。代码为CPT 92229，是首个无需专科医生监督即可在基层医疗报销的人工智慧专用代码，加速了人工智慧糖尿病视网膜病变筛检在美国的普及。例如，LumineticsCore（Digital Diagnostics）、EyeArt（Eyenuk）和AEYE-DS（AEYE Health）等系统皆以独立的诊断系统纳入报销范围。透过核准无需医生直接解读即可报销，美国联邦医疗保险和医疗补助服务中心（CMS）认可人工智慧并非实验性辅助手段，而是可报销的临床服务。这些政策变更有助于工作流程分散化，并支持在糖尿病门诊常规就诊期间进行现场筛检。因此，这些服务能够产生可预测的收入，医疗保健提供者也更积极地投资于人工智慧驱动的视网膜成像系统，以推动高品质医疗保健目标的实现。

目录

第一章：分析方法和范围

第二章执行摘要

第三章：美国人工智慧糖尿病视网膜病变筛检市场：影响因素、趋势和范围

  • 市场历史及展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 人工智慧驱动的糖尿病视网膜病变筛检市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析
  • 案例研究
  • 技术概述

第四章：美国人工智慧糖尿病视网膜病变筛检市场：按组件分類的估算和趋势分析

  • 美国人工智慧糖尿病视网膜病变筛检市场：按组件分類的波动分析
  • 美国人工智慧糖尿病视网膜病变筛检市场：市场规模和趋势分析：按组成部分划分（2021-2033 年）
  • 软体
  • 硬体
  • 服务

第五章：美国人工智慧糖尿病视网膜病变筛检市场：按筛检方法分類的估算和趋势分析

  • 美国人工智慧糖尿病视网膜病变筛检市场：按筛检方法分類的波动分析
  • 美国人工智慧糖尿病视网膜病变筛检市场：市场规模和趋势分析：按筛检方法划分（2021-2033 年）
  • 自主人工智慧筛检
  • 人工智慧辅助筛检
  • 基于远距眼科的筛检

第六章：美国人工智慧糖尿病视网膜病变筛检市场：按部署方式分類的估算与趋势分析

  • 美国人工智慧糖尿病视网膜病变筛检市场：按部署方式分類的波动分析
  • 美国人工智慧糖尿病视网膜病变筛检市场：市场规模与趋势分析：按部署方式划分（2021-2033 年）
  • 云
  • 现场
  • 杂交种

第七章：美国人工智慧糖尿病视网膜病变筛检市场：按最终用途分類的估算和趋势分析

  • 美国人工智慧糖尿病视网膜病变筛检市场：按最终用途分類的波动分析
  • 美国人工智慧糖尿病视网膜病变筛检市场：市场规模和趋势分析：按最终用途划分（2021-2033 年）
  • 医院
  • 眼科诊所
  • 基层医疗机构
  • 远距眼科医疗保健提供者
  • 其他的

第八章 竞争情势

  • 公司/竞争对手分类
  • 策略规划
  • 企业市场分析（2025 年）
  • 公司简介/列表
    • Eyenuk, Inc.
    • Digital Diagnostics Inc.
    • AEYE Health.
    • Optomed
    • IRIS（Intelligent Retinal Imaging Systems）
    • RETINA-AI Health, Inc.
    • iCare
    • RetinaRisk（by Risk Medical Solutions）
    • BeamMed Inc.
Product Code: GVR-4-68040-849-6

U.S. AI-driven Diabetic Retinopathy Screening Market Summary

The U.S. AI-driven diabetic retinopathy screening market size was estimated at USD 190.01 million in 2025 and is projected to reach USD 881.74 million by 2033, growing at a CAGR of 21.18% from 2026 to 2033. Rising prevalence of diabetes, favorable reimbursement pathways, and shortage of ophthalmologists and access gaps are significant factors contributing to market growth.

The country faces a growing public health challenge from diabetes, thereby increasing the population at risk of diabetic retinopathy. For instance, according to the data published by the U.S. Centers for Disease Control and Prevention in May 2024, around 38.4 million people were affected by diabetes, accounting for 11.6% of the total U.S. population. Furthermore, the American Academy of Ophthalmology reports that nearly 60 percent of individuals with diabetes do not attend their recommended annual dilated eye examinations, despite established clinical guidelines. This discrepancy between recommended care and actual adherence substantially elevates the risk of undiagnosed disease progression and preventable vision loss.

Diabetic patients are commonly managed in primary care or endocrinology settings, where retinal screening is frequently unavailable. As the prevalence of diabetes increases, the demand for annual eye examinations surpasses the capacity of available specialists. This results in a screening burden that conventional healthcare systems cannot address efficiently. Artificial intelligence-enabled diabetic retinopathy screening systems provide scalable, point-of-care solutions that do not require immediate specialist intervention. AI addresses detection gaps through autonomous and rapid diagnostics. Moreover, primary care integration expands access beyond specialists, enabling early intervention to prevent vision loss and comorbidities. For instance, in July 2023, Mount Sinai launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first in New York, to advance AI in ophthalmology for timely diagnosis of macular degeneration, diabetic retinopathy, glaucoma, hypertensive retinopathy, and retinal tumors. Partnering with the Windreich Department of AI and Human Health, it targets tele-retina, tele-ophthalmology, and eye stroke services using validated AI models.

Furthermore, in 2021, AI-driven eye disease diagnosis advanced significantly with the introduction of a new reimbursement code for AI-based diabetic retinopathy screening in the U.S. Medicare reimbursement accelerated the adoption of AI-based diabetic retinopathy screening in the country through CPT 92229, the first AI-specific code allowing primary care billing without specialist oversight. For instance, LumineticsCore (Digital Diagnostics), EyeArt (Eyenuk), and AEYE-DS (AEYE Health) have each received coverage as autonomous diagnostic systems. By authorizing reimbursement without direct physician interpretation, the Centers for Medicare & Medicaid Services (CMS) has recognized AI as a reimbursable clinical service rather than an experimental adjunct. These policy changes support workflow decentralization and enable screening at the point of care during routine diabetes visits. As a result, providers are more willing to invest in AI-enabled retinal imaging systems, since these services generate predictable revenue and advance quality care objectives.

U.S. AI-driven Diabetic Retinopathy Screening Market Report Segmentation

This report forecasts, revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented U.S. AI-driven diabetic retinopathy screening market report based on component, deployment mode, screening, and end use.

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software
  • Hardware
  • Services
  • Deployment Mode Outlook (Revenue, USD Million, 2021 - 2033)
  • Cloud-Based
  • On-Premise
  • Hybrid
  • Screening Outlook (Revenue, USD Million, 2021 - 2033)
  • Autonomous AI Screening
  • AI-Assisted Screening
  • Teleophthalmology-Based Screening
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Primary Care Settings
  • Hospitals
  • Ophthalmic Clinics
  • Teleophthalmology Providers
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Component Mode Segment
    • 1.2.2. Deployment Mode Segment
    • 1.2.3. Screening Segment
    • 1.2.4. End Use
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. U.S. AI-driven Diabetic Retinopathy Screening Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
    • 3.2.3. Market opportunity analysis
    • 3.2.4. Market challenges analysis
  • 3.3. AI-driven Diabetic Retinopathy Screening Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
      • 3.3.2.6. Social Landscape
  • 3.4. Case Studies
  • 3.5. Technology Overview

Chapter 4. U.S. AI-driven Diabetic Retinopathy Screening Market: Component Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. AI-driven Diabetic Retinopathy Screening Market Component Movement Analysis
  • 4.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
  • 4.4. Software
    • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Hardware
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Services
    • 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. U.S. AI-driven Diabetic Retinopathy Screening Market: Screening Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. AI-driven Diabetic Retinopathy Screening Market Screening Movement Analysis
  • 5.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by Screening, 2021 to 2033 (USD Million)
  • 5.4. Autonomous AI Screening
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. AI-Assisted Screening
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Teleophthalmology-Based Screening
    • 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. U.S. AI-driven Diabetic Retinopathy Screening Market: Deployment Mode Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. AI-driven Diabetic Retinopathy Screening Market Deployment Mode Movement Analysis
  • 6.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by Deployment Mode, 2021 to 2033 (USD Million)
  • 6.4. Cloud-Based
    • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. On-Premise
    • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Hybrid
    • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. AI-driven Diabetic Retinopathy Screening Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. AI-driven Diabetic Retinopathy Screening Market End Use Movement Analysis
  • 7.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5. Ophthalmic Clinics
    • 7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Primary Care Settings
    • 7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Teleophthalmology Providers
    • 7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8. Others
    • 7.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2025
  • 8.4. Company Profiles/Listing
    • 8.4.1. Eyenuk, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Digital Diagnostics Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. AEYE Health.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Optomed
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. IRIS (Intelligent Retinal Imaging Systems)
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. RETINA-AI Health, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. iCare
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. RetinaRisk (by Risk Medical Solutions)
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. BeamMed Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. AI-driven diabetic retinopathy screening market, by region, 2021 - 2033 (USD Million)
  • Table 3 U.S. AI-driven diabetic retinopathy screening market, by component, 2021 - 2033 (USD Million)
  • Table 4 U.S. AI-driven diabetic retinopathy screening market, by deployment mode, 2021 - 2033 (USD Million)
  • Table 5 U.S. AI-driven diabetic retinopathy screening market, by screening, 2021 - 2033 (USD Million)
  • Table 6 U.S. AI-driven diabetic retinopathy screening market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Market formulation & validation
  • Fig. 5 U.S. AI-driven diabetic retinopathy screening market: Market outlook
  • Fig. 6 U.S. AI-driven diabetic retinopathy screening market: Segment outlook
  • Fig. 7 U.S. AI-driven diabetic retinopathy screening market: Competitive landscape outlook
  • Fig. 8 Parent market outlook
  • Fig. 9 U.S. AI-driven diabetic retinopathy screening market driver impact
  • Fig. 10 U.S. AI-driven diabetic retinopathy screening market restraint impact
  • Fig. 11 U.S. AI-driven diabetic retinopathy screening market: Component outlook and key takeaways
  • Fig. 12 U.S. AI-driven diabetic retinopathy screening market: Component movement analysis
  • Fig. 13 Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 Hardware market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 15 Services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 U.S. AI-driven diabetic retinopathy screening market: Screening outlook and key takeaways
  • Fig. 17 U.S. AI-driven diabetic retinopathy screening market: Screening movement analysis
  • Fig. 18 Autonomous AI screening market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 AI-assisted screening market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Teleophthalmology-based screening market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 AI-driven diabetic retinopathy screening market: Deployment mode outlook and key takeaways
  • Fig. 22 AI-driven diabetic retinopathy screening market: Deployment mode movement analysis
  • Fig. 23 Cloud-based market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 On-premise market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Hybrid market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 AI-driven diabetic retinopathy screening market: End use outlook and key takeaways
  • Fig. 27 AI-driven diabetic retinopathy screening market: End use movement analysis
  • Fig. 28 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Ophthalmic clinics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Primary care settings market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Teleophthalmology providers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Others market estimates and forecasts, 2021 - 2033 (USD Million)